Clinical Trial Update: A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) [Phase 2]

View source ↗

Summary

Phase 2 study of efinopegdutide in participants with precirrhotic nonalcoholic steatohepatitis (NAFLD/NASH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Efinopegdutide (efinopegdutide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | Status: COMPLETED